Personalis (NASDAQ:PSNL) Trading Up 11.3% – Still a Buy?

Personalis, Inc. (NASDAQ:PSNL) shares traded up 11.3% during mid-day trading on Thursday . The company traded as high as $11.39 and last traded at $11.9980. 339,639 shares were traded during mid-day trading, a decline of 81% from the average session volume of 1,800,092 shares. The stock had previously closed at $10.78.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Wall Street Zen upgraded Personalis from a “sell” rating to a “hold” rating in a report on Saturday, May 30th. Morgan Stanley decreased their price objective on Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. BTIG Research decreased their price objective on Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a report on Monday, May 11th. Needham & Company LLC increased their price objective on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Personalis has an average rating of “Moderate Buy” and an average target price of $11.00.

Personalis Stock Up 14.2%

The firm has a fifty day moving average price of $7.09 and a two-hundred day moving average price of $8.16. The stock has a market capitalization of $1.29 billion, a P/E ratio of -12.02 and a beta of 2.28.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. The company had revenue of $15.47 million for the quarter, compared to the consensus estimate of $14.49 million. Sell-side analysts anticipate that Personalis, Inc. will post -1.06 earnings per share for the current fiscal year.

Insider Buying and Selling at Personalis

In related news, CFO Aaron Tachibana sold 38,799 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $11.58, for a total transaction of $449,292.42. Following the sale, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at $2,302,486.14. This trade represents a 16.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 80,091 shares of the stock in a transaction on Friday, May 29th. The shares were sold at an average price of $11.02, for a total value of $882,602.82. Following the sale, the chief executive officer directly owned 235,986 shares in the company, valued at $2,600,565.72. This trade represents a 25.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 138,799 shares of company stock worth $1,551,292 over the last ninety days. 4.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Personalis

Several institutional investors have recently modified their holdings of the business. Bank of America Corp DE boosted its position in shares of Personalis by 85.4% during the first quarter. Bank of America Corp DE now owns 111,306 shares of the company’s stock valued at $709,000 after buying an additional 51,273 shares during the last quarter. Janus Henderson Group PLC purchased a new stake in shares of Personalis during the first quarter valued at $192,000. ADAR1 Capital Management LLC purchased a new stake in shares of Personalis during the first quarter valued at $159,000. Sei Investments Co. boosted its position in shares of Personalis by 148.3% during the first quarter. Sei Investments Co. now owns 139,046 shares of the company’s stock valued at $886,000 after buying an additional 83,040 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Personalis by 8.4% during the first quarter. Dimensional Fund Advisors LP now owns 1,066,248 shares of the company’s stock valued at $6,791,000 after buying an additional 83,074 shares during the last quarter. 61.91% of the stock is owned by hedge funds and other institutional investors.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.